File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists

TitleSRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists
Authors
Keywordspolymorphism, single nucleotide
prostate
prostatic hyperplasia
SRD5A1 protein, human
SRD5A2 protein, human
Issue Date2013
Citation
Journal of Urology, 2013, v. 190, n. 2, p. 615-619 How to Cite?
AbstractPurpose: Common treatments for benign prostatic hyperplasia include 5α-reductase inhibitors and α-adrenergic receptor antagonists. However, these treatments can only partially decrease the risk of benign prostatic hyperplasia progression. SRD5A1 and SRD5A2 are 5α-reductase inhibitor targets. We investigated the association between drug efficacy and single nucleotide polymorphisms in the SRD5A1 and SRD5A2 genes in a Chinese population. Materials and Methods: We genotyped 11 tagging single nucleotide polymorphisms in the SRD5A1 and SRD5A2 genes in a total of 426 benign prostatic hyperplasia cases and 1,008 controls from Xinhua Hospital, Shanghai, People's Republic of China. Cases were treated with type II 5α-reductase inhibitors and α-adrenergic receptor antagonists. We tested the association of tagging single nucleotide polymorphisms with benign prostatic hyperplasia risk/progression, clinical characteristics at baseline, including the I-PSS (International Prostate Symptom Score) and total prostate volume, and changes in clinical characteristics after treatment. Results: The 11 tagging single nucleotide polymorphisms were not significantly associated with benign prostatic hyperplasia risk or progression (each p >0.05). In the SRD5A1 gene rs6884552 and rs3797177 were significantly associated with baseline I-PSS (p = 0.04 and 0.003, respectively). In the SRD5A2 gene rs523349 (V89L) and rs9332975 were significantly associated with baseline total prostate volume (p = 0.01 and 0.001, respectively). In SRD5A1 rs166050 was significantly associated with the posttreatment change in total prostate volume (p = 0.04). In SRD5A2 rs523349 and rs612224 were significantly associated with the posttreatment I-PSS change (p = 0.03 and 0.009, respectively). Conclusions: SRD5A1 and SRD5A2 single nucleotide polymorphisms are significantly associated with the clinical characteristics of benign prostatic hyperplasia and the efficacy of benign prostatic hyperplasia treatment. © 2013 American Urological Association Education and Research, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/314347
ISSN
2023 Impact Factor: 5.9
2023 SCImago Journal Rankings: 1.938
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorGu, Xin-
dc.contributor.authorNa, Rong-
dc.contributor.authorHuang, Tao-
dc.contributor.authorWang, Li-
dc.contributor.authorTao, Sha-
dc.contributor.authorTian, Lu-
dc.contributor.authorChen, Zhuo-
dc.contributor.authorJiao, Yang-
dc.contributor.authorKang, Jian-
dc.contributor.authorZheng, Siqun-
dc.contributor.authorXu, Jianfeng-
dc.contributor.authorSun, Jielin-
dc.contributor.authorQi, Jun-
dc.date.accessioned2022-07-20T12:03:42Z-
dc.date.available2022-07-20T12:03:42Z-
dc.date.issued2013-
dc.identifier.citationJournal of Urology, 2013, v. 190, n. 2, p. 615-619-
dc.identifier.issn0022-5347-
dc.identifier.urihttp://hdl.handle.net/10722/314347-
dc.description.abstractPurpose: Common treatments for benign prostatic hyperplasia include 5α-reductase inhibitors and α-adrenergic receptor antagonists. However, these treatments can only partially decrease the risk of benign prostatic hyperplasia progression. SRD5A1 and SRD5A2 are 5α-reductase inhibitor targets. We investigated the association between drug efficacy and single nucleotide polymorphisms in the SRD5A1 and SRD5A2 genes in a Chinese population. Materials and Methods: We genotyped 11 tagging single nucleotide polymorphisms in the SRD5A1 and SRD5A2 genes in a total of 426 benign prostatic hyperplasia cases and 1,008 controls from Xinhua Hospital, Shanghai, People's Republic of China. Cases were treated with type II 5α-reductase inhibitors and α-adrenergic receptor antagonists. We tested the association of tagging single nucleotide polymorphisms with benign prostatic hyperplasia risk/progression, clinical characteristics at baseline, including the I-PSS (International Prostate Symptom Score) and total prostate volume, and changes in clinical characteristics after treatment. Results: The 11 tagging single nucleotide polymorphisms were not significantly associated with benign prostatic hyperplasia risk or progression (each p >0.05). In the SRD5A1 gene rs6884552 and rs3797177 were significantly associated with baseline I-PSS (p = 0.04 and 0.003, respectively). In the SRD5A2 gene rs523349 (V89L) and rs9332975 were significantly associated with baseline total prostate volume (p = 0.01 and 0.001, respectively). In SRD5A1 rs166050 was significantly associated with the posttreatment change in total prostate volume (p = 0.04). In SRD5A2 rs523349 and rs612224 were significantly associated with the posttreatment I-PSS change (p = 0.03 and 0.009, respectively). Conclusions: SRD5A1 and SRD5A2 single nucleotide polymorphisms are significantly associated with the clinical characteristics of benign prostatic hyperplasia and the efficacy of benign prostatic hyperplasia treatment. © 2013 American Urological Association Education and Research, Inc.-
dc.languageeng-
dc.relation.ispartofJournal of Urology-
dc.subjectpolymorphism, single nucleotide-
dc.subjectprostate-
dc.subjectprostatic hyperplasia-
dc.subjectSRD5A1 protein, human-
dc.subjectSRD5A2 protein, human-
dc.titleSRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.juro.2013.03.024-
dc.identifier.pmid23499746-
dc.identifier.scopuseid_2-s2.0-84880046114-
dc.identifier.volume190-
dc.identifier.issue2-
dc.identifier.spage615-
dc.identifier.epage619-
dc.identifier.eissn1527-3792-
dc.identifier.isiWOS:000321436600073-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats